Back to top
more

Stryker (SYK)

(Delayed Data from NYSE)

$376.37 USD

376.37
1,176,747

+1.43 (0.38%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $376.43 +0.06 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (156 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Integra's (IART) Q4 Earnings Miss Estimates, Margins Down

by Zacks Equity Research

Integra's (IART) Q4 revenues are impacted by the decline in the Tissue Technologies segment.

Zacks Equity Research

National Vision (EYE) Q4 Earnings Top Estimates, Margins Fall

by Zacks Equity Research

National Vision's (EYE) Q4 adjusted comparable store sales growth is driven by ongoing strength within America's Best and Eyeglass World sales.

Zacks Equity Research

Chemed (CHE) Q4 Earnings Surpass Estimates, Margins Expand

by Zacks Equity Research

Chemed's (CHE) fourth-quarter 2023 performance reflects an improvement in VITAS' operational metrics.

Zacks Equity Research

Insulet (PODD) Q4 Earnings, Revenues Top Mark, Margins Expand

by Zacks Equity Research

In the fourth quarter, Insulet (PODD) achieves the milestone of 425,000 estimated active global customers using Omnipod products.

Zacks Equity Research

Myriad Genetics (MYGN) Q4 Earnings Top Estimate, Margins Down

by Zacks Equity Research

Myriad Genetics (MYGN) registers a strong testing volume improvement across all its businesses in the fourth quarter of 2023.

Zacks Equity Research

Alcon (ALC) Q4 Earnings Beat Estimates, Margins Expand

by Zacks Equity Research

Alcon (ALC) delivers impressive performance across its franchises in the fourth quarter of 2023.

Zacks Equity Research

Here's Why Investors Should Retain STERIS (STE) Stock for Now

by Zacks Equity Research

Investors are optimistic about STERIS (STE) on continuous recovery of healthcare procedures and upbeat 2024 guidance.

Zacks Equity Research

Quest Diagnostics' (DGX) New Pact to Reduce Food Insecurity

by Zacks Equity Research

Quest Diagnostics' (DGX) recent collaboration aims to advance food access and healthy eating habits for underserved communities.

Zacks Equity Research

HAE or SYK: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

HAE vs. SYK: Which Stock Is the Better Value Option?

Zacks Equity Research

Henry Schein (HSIC) Q4 Earnings Miss, Operating Margin Down

by Zacks Equity Research

Henry Schein (HSIC) posts lower-than-expected earnings and revenues in the fourth quarter of 2023.

Zacks Equity Research

Here's Why You Should Buy Edward Lifesciences (EW) Stock Now

by Zacks Equity Research

Investors are optimistic about Edward Lifesciences' (EW) progress with the Structural Heart business and strong TAVR potential.

Zacks Equity Research

Penumbra (PEN) Q4 Earnings Top Estimates, Margins Increase

by Zacks Equity Research

Penumbra's (PEN) Q4 revenues register year-over-year growth driven by robust U.S. thrombectomy sales.

Zacks Equity Research

Here's Why Investors Should Hold Labcorp (LH) Stock for Now

by Zacks Equity Research

Targeted development in high-growth areas and strategic partnerships bode well for Labcorp (LH).

Zacks Equity Research

Amedisys' (AMED) Q4 Earnings Miss Estimates, Margins Up

by Zacks Equity Research

The continuous shortage of clinical labor, nursing in particular, is likely to have impacted Amedisys' (AMED) Q4 performance.

Zacks Equity Research

Teleflex (TFX) Q4 Earnings Top Estimates, Operating Margin Falls

by Zacks Equity Research

Teleflex (TFX) surpasses earnings and revenue estimates in the fourth quarter of 2023.

Zacks Equity Research

Veracyte's (VCYT) Q4 Loss Widens, Gross Margin Expands

by Zacks Equity Research

Veracyte's (VCYT) fourth-quarter 2023 performance reflects solid financial discipline and the strength of the Decipher Prostate and Afirma tests.

Zacks Equity Research

ICON (ICLR) Q4 Earnings Surpass Estimates, Margins Expand

by Zacks Equity Research

ICON's (ICLR) solid performance in the fourth quarter reflects continued market leadership across customer segments it serves.

Zacks Equity Research

Exact Sciences (EXAS) Q4 Loss Narrows, Revenues Rise Y/Y

by Zacks Equity Research

Robust revenues from Exact Sciences' (EXAS) Screening and Precision Oncology segments contribute to the fourth-quarter top line.

Zacks Equity Research

Tandem Diabetes (TNDM) Posts Wider Q4 Loss, Gross Margin Down

by Zacks Equity Research

Tandem Diabetes (TNDM) reports a higher-than-expected loss in the fourth quarter of 2023.

Zacks Equity Research

Here's Why You Should Retain Align Technology (ALGN) Stock Now

by Zacks Equity Research

Investors are optimistic about Align Technology (ALGN) on continued geographic expansion.

Zacks Equity Research

Boston Scientific (BSX) Surges 4.6%: Will the Rally Continue?

by Zacks Equity Research

Boston Scientific (BSX) is benefitting from an impressive gain in MedSurg market share and the strong adoption of WATCHMAN FLX.

Zacks Equity Research

Charles River (CRL) Gains From CRADL Amid Soft Market Scenario

by Zacks Equity Research

Within DSA, Charles River (CRL) is currently the largest provider of outsourced drug discovery, non-clinical development and regulated safety testing services worldwide.

Zacks Equity Research

Sight Sciences (SGHT) to Expand in Europe With New Launch

by Zacks Equity Research

By tapping into the European market, Sight Sciences (SGHT) aims to capitalize on the growing demand for advanced eye care technologies.

Zacks Equity Research

Here's Why You Should Buy Zimmer Biomet (ZBH) Stock Now

by Zacks Equity Research

Strategic plans to drive the Knee business bode well for Zimmer Biomet (ZBH).

Zacks Equity Research

Globus Medical (GMED) Q4 Earnings Surpass, Margins Down

by Zacks Equity Research

Globus Medical's (GMED) fourth-quarter 2023 performance benefits from innovative launches across its product groups.